肺癌诊治和预后判断分子标志物miRNA

吉丛; 喻长远; 陈志华

doi:10.3969/j.issn.1000-8179.20140754

肺癌诊治和预后判断分子标志物miRNA

doi: 10.3969/j.issn.1000-8179.20140754

吉丛^①,,
喻长远^①,
陈志华^②, ,

①.
北京化工大学生命科学与技术学院（北京市100029）
②.
中日友好医院，临床医学研究所生物化学与分子生物学研究室

详细信息

作者简介:
吉丛专业方向为肺癌的分子诊断。E-mail：ji2016389@163.com

通讯作者:
陈志华 chzhihua@sina.com

计量
- 文章访问数: 34
- HTML全文浏览量: 34
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-05
- 修回日期: 2014-08-20
- 刊出日期: 2020-12-29

Molecular marker miRNA for the diagnosis, treatment and prognosis of lung cancer

JI Cong^{①
,},
YU Changyuan^①,
CHEN Zhihua^{②
, ,}

①.
College of Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China
②.
Department of Biochemistry and Molecular Biology, Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, Beijing 100029, China

More Information

Corresponding author: Zhihua CHEN; E-mail: chzhihua@sina.com

摘要

摘要: 肺癌是目前全世界发病率第一、死亡率最高的肿瘤。肺癌的早期诊断和有效治疗是提高患者生存率的关键。miRNA是一类内源性、高度保守的非编码小分子RNA，在肺癌的发生、发展中起着重要作用。近年来，肺癌诊断、治疗和预后判断分子标志物miRNA的研究进展迅速，本文就miRNA作为肺癌早期诊断、预后判断和疗效预测分子标志物的研究进展，以及目前存在的问题做一综述。
- 肺癌 /
- miRNA /
- 诊断 /
- 预后 /
- 治疗
Abstract: Lung cancer has the highest morbidity and mortality rate among malignant tumors. Early diagnosis and effective treatment are the keys to improving the survival of lung cancer patients. A type of endogenous, highly conserved, non-coding small molecule RNA (i.e., miRNA) was found to play an important role in the occurrence and development of this disease. Research on this molecular marker miRNA for the diagnosis, treatment and prognosis of lung cancer has rapidly progressed. This paper reviews the research work on miRNA as a molecular marker in the early diagnosis, treatment efficacy, and prognosis of lung cancer and explores some questions related to this disease.
- lung cancer /
- miRNA /
- diagnosis /
- prognosis /
- treatment

HTML全文

参考文献(26)

[1]	Rebecca S, Deepa N, Ahmedin J.Cancer Statistics[J]. CA CANCER J CLIN, 2013, 34(4):24-29.
[2]	Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating microRNA expression profiles in early stage nonsmall cell lung cancer[J]. Int J Cancer, 2012, 130(6):1378-1386. doi: 10.1002/ijc.26153
[3]	Chen X, Hu ZB, Wang WJ, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis[J]. Int J Cancer, 2012, 130(7):1620-1628. doi: 10.1002/ijc.26177
[4]	Tang DF, Shen Y, Wang MZ, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer[J]. European Journal of Cancer Prevention, 2013, 22 (6):540-548. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW201705250521062
[5]	Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer[J]. Gene, 2014, 534(1):60-65. http://cn.bing.com/academic/profile?id=65365b8caa3cb196a2958f2931f79770&encoded=0&v=paper_preview&mkt=zh-cn
[6]	Xie Y, Todd NW, Liu ZQ, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer[J]. Lung Cancer, 2010, 67(2):170-176. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=9b0dce41c31c93e75a680025126835b6
[7]	Roth C, Kasimir-Bauer S, Pantel K, et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer[J]. Mol Oncol, 2011, 5(3):281-291. http://cn.bing.com/academic/profile?id=9e4adbeabf4c711b92dcb7bce4106d62&encoded=0&v=paper_preview&mkt=zh-cn
[8]	Hamamoto J, Soejima K, Yoda S, et al. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma[J]. Mol Med Rep, 2013, 8(2):456-462. doi: 10.3892/mmr.2013.1517
[9]	Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers[J]. Mod. Pathol. 2010, (23):1157-1164. doi: 10.1038/modpathol.2010.111
[10]	Yu L, Todd NW, Xing L. et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers[J]. Int. J. Cancer, 2010, 127(12):2070-2078. http://cn.bing.com/academic/profile?id=dc79d01310e5ef300518194ec612c839&encoded=0&v=paper_preview&mkt=zh-cn
[11]	Hennessey PT, Sanford T, Choudhary A, et al. Serum miRNA biomarkers for detection of non-small cell lung cancer[J]. PLoS One, 2012, 7(2):e32307. doi: 10.1371/journal.pone.0032307
[12]	Arora S, Ranade AR, Tran NL, et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration[J]. Int J Cancer, 2011, 129(11):2621-2631. doi: 10.1002/ijc.25939
[13]	Yang MM, Shen HC, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer[J]. European Journal of Cancer 2013, 49(3):604-615. doi: 10.1016/j.ejca.2012.09.031
[14]	Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts[J]. Clin Cancer Res, 2011, 17(7):1875-1882. doi: 10.1158/1078-0432.CCR-10-2961
[15]	Zhu.W, Liu X, He J, et al. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study[J]. BMC Cancer, 2011, 11:393. doi: 10.1186/1471-2407-11-393
[16]	Voortman J, Goto A, Mendiboure J, MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma[J]. Cancer Res, 2010, 70(21):8288-8298. doi: 10.1158/0008-5472.CAN-10-1348
[17]	Tan XG, Qin WY, Zhang L, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis[J]. Clin Cancer Res, 2011, 17(21):6802-6811. doi: 10.1158/1078-0432.CCR-11-0419
[18]	Kaduthanam S, Gade S, Meister M, et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients[J]. Lung Cancer, 2013, 80(2):223-227. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=1db6c604c1c04b990219a51bc306584f
[19]	Cao JZ, Song YM, Bi N, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer[J]. Cancer Res, 2013, 73(11):3326-3335. doi: 10.1158/0008-5472.CAN-12-3055
[20]	Landi MT, Zhao YD, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer[J]. Clin Cancer Res, 2010, 16(2):430-441. doi: 10.1158/1078-0432.CCR-09-1736
[21]	Berghmans T, Ameye L, Willems L, et al. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study[J]. Lung Cancer, 2013, 82(2):340-345. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=604d11d23c890f2e33e38967cce7fc8c
[22]	Cui EH, Li HJ, Hua F, et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy[J]. Acta Pharmacol Sin, 2013, 34(2): 309-313. http://cn.bing.com/academic/profile?id=bf71641f4338d7841fd7c9f8cf830d3c&encoded=0&v=paper_preview&mkt=zh-cn
[23]	Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer[J]. J Cell Physiol, 2014, 229(1):97-99. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=883ec045637b3cc9c6a33b227385e904
[24]	Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines[J]. Ann Oncol, 2008, 19(6):1053-1059. doi: 10.1093/annonc/mdn006
[25]	Lee KM, Choi EJ, Kim IA. MicroRNA-7 increases radiosensitivity of hunman cancer cells with activated EGFR-associated singaling [J]. Radiother Oncol, 2011, 101(1):171-176. https://www.sciencedirect.com/science/article/pii/S016781401100243X
[26]	Wang XC, Du LQ, Tian LL, et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resisitant patients of non-small cell lung cancer[J]. Lung Cancer, 2011, 72(1):92-99. https://www.ncbi.nlm.nih.gov/pubmed/20728239